Paul M. Karpecki, OD, FAAO

Following a discussion on low-dose atropine, Paul Karpecki, OD, FAAO, shares his views on what the future of myopia management looks like.

Paul Karpecki, OD, FAAO, sits down to discuss Sydnexis's atropine formulation and what an FDA approval would mean for myopia management.

Earlier and proactive use is suggested for a variety of corneal diseases